Methods of T Cell Depletion Trial (MoTD)

This study is looking for adults aged between 16 and 70 who have certain blood cancers like specific types of leukaemia, lymphoma, or myeloma, and are planning to have a stem cell transplant from an unrelated donor. It's important that a suitable donor has been found for you, meaning their cells are a good match for yours. You also need to be planning to receive stem cells collected from the blood.

There are specific rules about the types of chemotherapy you will receive before your transplant; your doctor will know if your planned treatment fits these criteria. You cannot join if you have certain other serious health issues, such as severe heart or kidney problems, or if you are pregnant or breastfeeding. Also, if you are currently taking part in certain other specific trials (like COSI or ALL-RIC), you won't be able to join this one.

If you decide to take part in this study, you will be randomly assigned to one of three treatment groups by chance, like flipping a coin. This means neither you nor your doctor can choose which group you are in. Each group will receive a different set of medicines aimed at preventing GvHD after your stem cell transplant. For example, some might get Thymoglobulin, while others get Cyclophosphamide combined with Cyclosporine or Sirolimus.

Beyond your standard transplant care, the study will involve regular check-ups and tests. These will help your doctors monitor your recovery, look for any signs of GvHD, and check how well the treatment is working and if you experience any side effects. The study will track your health over time, involving follow-up visits and assessments for many months, potentially up to several years, to understand the long-term effects of each treatment approach. You'll also be asked about your quality of life.